Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
See detailHémoglobine glyquée décentralisée
Gillery, P.; Bordas-Fonfrère, M.; Chapelle, Jean-Paul ULiege et al

Poster (1999, November)

Detailed reference viewed: 10 (0 ULiège)
Full Text
See detailHemolymph - Arthropoda : Chapter 2
Jeuniaux, Charles ULiege

in Florkin, M.; Scheer, B.T. (Eds.) Chemical zoology, volume VI, Arthropoda, part B (1971)

Detailed reference viewed: 34 (1 ULiège)
Full Text
See detailHemolymph : composition. Chapter 2
Florkin, Marcel ULiege; Jeuniaux, Charles ULiege

in Physiology of insect. Volume 3 (1964)

Detailed reference viewed: 27 (0 ULiège)
Full Text
See detailHemolymph: composition
Florkin, Marcel ULiege; Jeuniaux, Charles ULiege

in Rockstein, Morris (Ed.) The physiology of insecta, Volume V (1974)

Detailed reference viewed: 47 (5 ULiège)
Peer Reviewed
See detailHemolytic activity of new linear surfactin analogs
Dufour, Samuel; Deleu, Magali ULiege; Wathelet, Bernard ULiege et al

Poster (2005)

Detailed reference viewed: 19 (0 ULiège)
Full Text
Peer Reviewed
See detailHemolytic activity of new linear surfactin analogs in relation to their physico-chemical properties
Dufour, Samuel; Deleu, Magali ULiege; Nott, Katherine ULiege et al

in Biochimica et Biophysica Acta - General Subjects (2005), 1726

New linear analogs of surfactin have been synthesized. Their physico-chemical parameters were determined. The results indicate that these linear products show surface activities although they are lowered ... [more ▼]

New linear analogs of surfactin have been synthesized. Their physico-chemical parameters were determined. The results indicate that these linear products show surface activities although they are lowered compared to those of cyclic compounds. The hemolytic activities have also been assayed. In contrast with cyclic surfactins, no significant hemolysis occurs for the linear products in the range of concentrations tested. Moreover, a protective effect against Triton X-100 induced hemolysis has been highlighted for linear surfactins. The concentration at which this protective effect happens is correlated directly to the CMC, and inversely to the acyl chain length of the product. In a hypotonic medium, analogs having a long acyl chain tend to increase the hemolysis, meanwhile the product with the shortest chain tends to decrease it. [less ▲]

Detailed reference viewed: 58 (4 ULiège)
Full Text
Peer Reviewed
See detailHemolytic crisis induced by rasburicase administration revealing G-6-PD deficiency.
SID, Sélim ULiege; Dugauquier, D.; DE PRIJCK, Bernard ULiege et al

in Belgian Journal of Hematology (2014)

Detailed reference viewed: 52 (9 ULiège)
Full Text
Peer Reviewed
See detailHemolytic uremic syndrome with an atypical presentation.
NOGUE KAMDJE, Alain ULiege; BRASSEUR, Edmond ULiege; fournier et al

in Revue Médicale de Liège (2010), 65(12), 676-80

RÉ SUMÉ : Le syndrome hémolytique urémique (SHU ) est une affection assez rare chez l’adulte, mais de pronostic réservé. Il traduit une microangiopathie thrombotique essentiellement rénale. Nous ... [more ▼]

RÉ SUMÉ : Le syndrome hémolytique urémique (SHU ) est une affection assez rare chez l’adulte, mais de pronostic réservé. Il traduit une microangiopathie thrombotique essentiellement rénale. Nous rapportons l’histoire d’un jeune patient dont la présentation et l’exploration cliniques rendent le diagnostic de SHU probable. La présentation quelque peu atypique offre non seulement l’occasion de discuter des différents éléments qui plaident en faveur du diagnostic selon les hypothèses physiopathologiques les plus récentes, mais aussi de redéfinir les recommandations de la prise en charge en urgence de cette affection sévère. [less ▲]

Detailed reference viewed: 80 (6 ULiège)
Full Text
Peer Reviewed
See detailHemoreactivity of poly (dimethyl-aminoethyl-methacrylate) designed for the production of stealth red blood cells
Cerda, B; Pérez, E; Flores, H et al

Poster (2009, April 01)

Detailed reference viewed: 14 (0 ULiège)
Full Text
Peer Reviewed
See detailHemoreactivity of polymeric carriers designed for drug delivery systems
Grandfils, Christian ULiege; Sevrin, Chantal ULiege

in Proceeding Biomedica 2013 (2013, June 19)

Detailed reference viewed: 13 (0 ULiège)
Peer Reviewed
See detailL’hémorragie cérébrale : le coup de tonnerre dans un ciel serein
Martin, Didier ULiege

Conference (2008, October 23)

Detailed reference viewed: 8 (0 ULiège)
Full Text
Peer Reviewed
See detailL'hémorragie pulmonaire induite par l'exercise chez le cheval
Art, Tatiana ULiege; Lekeux, Pierre ULiege

in Pratique Vétérinaire Equine (1994), 26(1), 15-24

This review analyses the epidemiology, etiology, anatomo- and physiopathology, diagnosis and prevention of the syndrome of exercise-induced pulmonary hemorrhage in horses.

Detailed reference viewed: 97 (14 ULiège)
See detailHémorragie sous-arachnoïdienne et anévrisme artériel intra-crânien
Martin, Didier ULiege

Conference (2002, February 22)

Detailed reference viewed: 22 (2 ULiège)
Full Text
Peer Reviewed
See detailHémorragies cérébro-méningées par rupture d'anévrysme artériel intracrânien
Pirotte, B.; Born, JD.; HANS, Pol ULiege et al

in Revue Médicale de Liège (1992), 18

Detailed reference viewed: 17 (1 ULiège)
Peer Reviewed
See detailHémorragies sub-épendymaires et intraventriculaires chez le prémature eutrophique de 34 semaines de gestation et moins
Debauche, C; Langhendries; withofs L, L et al

in Revue Médicale de Liège (1986), 41

Detailed reference viewed: 12 (4 ULiège)
Full Text
Peer Reviewed
See detailHemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor.
Spyropoulos, Demetri D.; Pharr, Pamela N.; Lavenburg, Kim R. et al

in Molecular & Cellular Biology (2000), 20(15), 5643-5652

The Ets family of transcription factors have been suggested to function as key regulators of hematopoeisis. Here we describe aberrant hematopoeisis and hemorrhaging in mouse embryos homozygous for a ... [more ▼]

The Ets family of transcription factors have been suggested to function as key regulators of hematopoeisis. Here we describe aberrant hematopoeisis and hemorrhaging in mouse embryos homozygous for a targeted disruption in the Ets family member, Fli1. Mutant embryos are found to hemorrhage from the dorsal aorta to the lumen of the neural tube and ventricles of the brain (hematorrhachis) on embryonic day 11.0 (E11.0) and are dead by E12.5. Histological examinations and in situ hybridization reveal disorganization of columnar epithelium and the presence of hematomas within the neuroepithelium and disruption of the basement membrane lying between this and mesenchymal tissues, both of which express Fli1 at the time of hemorrhaging. Livers from mutant embryos contain few pronormoblasts and basophilic normoblasts and have drastically reduced numbers of colony forming cells. These defects occur with complete penetrance of phenotype regardless of the genetic background (inbred B6, hybrid 129/B6, or outbred CD1) or the targeted embryonic stem cell line used for the generation of knockout lines. Taken together, these results provide in vivo evidence for the role of Fli1 in the regulation of hematopoiesis and hemostasis. [less ▲]

Detailed reference viewed: 69 (24 ULiège)
Peer Reviewed
See detailHemostasis Profile in Women Taking Low-Dose Oral Contraceptives
David, Jean-Louis ULiege; Gaspard, U. J.; Gillain, Daniel ULiege et al

in American Journal of Obstetrics and Gynecology (1990), 163(1, Pt 2), 420-3

Thirty-six young, healthy, nonsmoking women have been selected to check the effect of low-dose oral contraceptives on hemostasis. Two identical groups were treated by Marvelon (a monophasic oral ... [more ▼]

Thirty-six young, healthy, nonsmoking women have been selected to check the effect of low-dose oral contraceptives on hemostasis. Two identical groups were treated by Marvelon (a monophasic oral contraceptive containing ethinyl estradiol and desogestrel) or Trigynon (a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel) for a 6-month period. In the absence, previously controlled, of substantial differences between the effects of each treatment on hemostasis, all the results were pooled at the third and sixth month of the study. The effects of oral contraceptive treatment were as follows: (1) platelet number, platelet aggregating ratio, and plasma beta-thromboglobulin level were not significantly altered, and (2) antithrombin III activity was not reduced despite a slight decrease or antigen concentration. The von Willebrand factor parameters, factor VIII:C, factor VII:C, and clottable fibrinogen were significantly increased. Plasminogen (activity and antigen concentrates) and alpha 2-antiplasmin levels were also significantly increased. Activated partial thromboplastin time and euglobulin lysis time measured after venous occlusion were significantly shortened. Although statistical analysis did not show dramatic changes in all these parameters, some individual extreme values were substantially altered. Therefore we believe that these later values are worthy of cautious consideration for weighing the role that hemostasis factors might play in individual thrombotic risk. [less ▲]

Detailed reference viewed: 15 (0 ULiège)
Peer Reviewed
See detailHemovigilance: Clinical Tolerance of Solvent-Detergent Treated Plasma
Baudoux, Etienne ULiege; Margraff, U.; Coenen, Alain ULiege et al

in Vox Sanguinis (1998), 74(Suppl 1), 237-9

OBJECTIVE: This study was conducted to assess retrospectively the clinical tolerance of SD treated plasma and to compare it to other labile blood products (red blood cell and platelet concentrates ... [more ▼]

OBJECTIVE: This study was conducted to assess retrospectively the clinical tolerance of SD treated plasma and to compare it to other labile blood products (red blood cell and platelet concentrates). METHODS: Adverse events (AEs) related to the use of blood products at the Blood Transfusion Center (BTC) are routinely collected through a formalised system of hemovigilance. All AEs reported are entered into a safety data base which was used for the study. All AEs reported during a one-year period to the BTC were retrospectively re-assessed and descriptive statistics calculated. RESULTS: 5064 units of SD treated plasma were transfused to 894 recipients during the study period at the occasion of 1553 transfusions. No AE associated to SD treatment plasma was reported during that period. In contrast, during the same period, 485 AEs associated with the use of red blood cell concentrates (RBCC) were reported in 251 patients at the occasion of 262 transfusions. 2.1% (251/11,748) of the patients transfused with RBCC experienced one or more AEs. The incidence of AEs per unit transfused was 1.3% (485/37,332), and 2.4% (485/20,460) of RBCC transfusions were associated with one or more AEs. 142 AEs associated with the use of platelet concentrate (PC) were observed in 69 patients at the occasion of 73 transfusions. 4.2% (69/1645) of patients transfused with PC experienced one or more AEs. The incidence of AEs per unit transfused was 1.1% (142/12,772), and 2.8% (142/5034) of PC transfusions were associated with one or more AEs. All reported AEs were classified and non serious. The most frequently observed AEs were fever, chills and rashes which accounted for roughly 64% of all reported AEs. CONCLUSION: As for the overall clinical tolerance of red cell and platelet concentrates, the results of this study are in complete agreement with the published literature. The study also confirms the extremely good tolerability of SD treated plasma in comparison with other labile blood products. [less ▲]

Detailed reference viewed: 27 (5 ULiège)